Skip to main content
Erschienen in: Journal of Gastroenterology 7/2018

19.12.2017 | Original Article—Liver, Pancreas, and Biliary Tract

The recovery of the PT-INR to less than 1.3 predicts survival in patients with severe acute liver injury

verfasst von: Seiichi Mawatari, Akihiro Moriuchi, Fuminori Ohba, Tetsu Kawano, Kohei Oda, Yasuhiro Takikawa, Hajime Takikawa, Akio Ido, Hirohito Tsubouchi

Erschienen in: Journal of Gastroenterology | Ausgabe 7/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Acute liver failure is a potentially fatal disease of various etiologies for which liver transplantation is the only known curative treatment. Although the decision-making on transplantation is largely dependent on the severity of liver injury (based on predicting a fatal outcome), a statistical analysis to predict “survival” has not been extensively conducted. In this study, we investigate the medical history of patients in two distinct areas of Japan with the aim of identifying the predictors of survival in patients with acute liver injury (ALI).

Methods

Datasets of 301 patients with ALI in two distinct areas (93 in southern Kyushu and 208 in northern Tohoku) of Japan, who were treated from 2004 to 2014, were included in the analysis.

Results

Among the enrolled 301 cases, 263 patients survived without transplantation. A PT-INR of ≥ 1.3 during the clinical course was found to be adequate for predicting a poor prognosis, because all of the fatal cases emerged from this population (hazard ratios: southern Kyushu, 0.2827; northern Tohoku, 0.1862). All surviving patients showed a reduction in their PT-INR during treatment, whereas the PT-INR did not decrease in the patients with a poor prognosis. A PT-INR of < 1.3 on days 7 and 8 efficiently predicted transplant-free survival (log-rank test: southern Kyushu, P = 0.0030; northern Tohoku, P = 0.0022).

Conclusions

A PT-INR of ≥ 1.3 during the clinical course might identify cases with a poor prognosis, while the recovery of the PT-INR to < 1.3 predicts transplant-free survival.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat O’Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. Lancet. 1993;342:273–5.CrossRefPubMed O’Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. Lancet. 1993;342:273–5.CrossRefPubMed
2.
Zurück zum Zitat Bernal W, Hyyrylainen A, Gera A, et al. Lessons from look-back in acute liver failure? A single centre experience of 3300 patients. J Hepatol. 2013;59:74–80.CrossRefPubMed Bernal W, Hyyrylainen A, Gera A, et al. Lessons from look-back in acute liver failure? A single centre experience of 3300 patients. J Hepatol. 2013;59:74–80.CrossRefPubMed
4.
Zurück zum Zitat Mochida S, Nakayama N. Acute liver failure and late onset hepatic failure (LOHF) in Japan (2014). Annual Report of the Study Group of Intractable Hepato-Biliary Study Group in Japan Supported by the Ministry of Health, Labor, and Welfare. 2016:116–35 (in Japanese). Mochida S, Nakayama N. Acute liver failure and late onset hepatic failure (LOHF) in Japan (2014). Annual Report of the Study Group of Intractable Hepato-Biliary Study Group in Japan Supported by the Ministry of Health, Labor, and Welfare. 2016:116–35 (in Japanese).
5.
Zurück zum Zitat Oketani M, Ido A, Nakayama N, et al. Etiology and prognosis of fulminant hepatitis and late-onset hepatic failure in Japan: summary of the annual nationwide survey between 2004 and 2009. Hepatol Res. 2013;43:97–105.CrossRefPubMed Oketani M, Ido A, Nakayama N, et al. Etiology and prognosis of fulminant hepatitis and late-onset hepatic failure in Japan: summary of the annual nationwide survey between 2004 and 2009. Hepatol Res. 2013;43:97–105.CrossRefPubMed
6.
Zurück zum Zitat Mochida S, Takikawa Y, Nakayama N, et al. Diagnostic criteria of acute liver failure: a report by the Intractable Hepato-Biliary Diseases Study Group of Japan. Hepatol Res. 2011;41:805–12.CrossRefPubMed Mochida S, Takikawa Y, Nakayama N, et al. Diagnostic criteria of acute liver failure: a report by the Intractable Hepato-Biliary Diseases Study Group of Japan. Hepatol Res. 2011;41:805–12.CrossRefPubMed
7.
Zurück zum Zitat Fujiwara K, Yasui S, Yonemitsu Y, et al. Efficacy of high-dose corticosteroid in the early stage of viral acute liver failure. Hepatol Res. 2014;44:491–501.CrossRefPubMed Fujiwara K, Yasui S, Yonemitsu Y, et al. Efficacy of high-dose corticosteroid in the early stage of viral acute liver failure. Hepatol Res. 2014;44:491–501.CrossRefPubMed
8.
Zurück zum Zitat Takikawa Y, Endo R, Suzuki K, et al. Early prediction of short-term development of hepatic encephalopathy in patients with acute liver disease unrelated to paracetamol. A prospective study in Japan. J Hepatol. 2009;51:1021–9.CrossRefPubMed Takikawa Y, Endo R, Suzuki K, et al. Early prediction of short-term development of hepatic encephalopathy in patients with acute liver disease unrelated to paracetamol. A prospective study in Japan. J Hepatol. 2009;51:1021–9.CrossRefPubMed
9.
Zurück zum Zitat Ueno Y, Ohmi T, Yamamoto M, et al. Orally-administered caspase inhibitor PF-03491390 is retained in the liver for prolonged periods with low systemic exposure, exerting a hepatoprotective effect against alpha-fas-induced liver injury in a mouse model. J Pharmacol Sci. 2007;105:201–5.CrossRefPubMed Ueno Y, Ohmi T, Yamamoto M, et al. Orally-administered caspase inhibitor PF-03491390 is retained in the liver for prolonged periods with low systemic exposure, exerting a hepatoprotective effect against alpha-fas-induced liver injury in a mouse model. J Pharmacol Sci. 2007;105:201–5.CrossRefPubMed
10.
Zurück zum Zitat Nalpas B, Ichai P, Jamot L, et al. A proof of concept, phase II randomized European trial, on the efficacy of ALF-5755, a novel extracellular matrix-targeted antioxidant in patients with acute liver diseases. PLoS One. 2016;11:e0150733.CrossRefPubMedPubMedCentral Nalpas B, Ichai P, Jamot L, et al. A proof of concept, phase II randomized European trial, on the efficacy of ALF-5755, a novel extracellular matrix-targeted antioxidant in patients with acute liver diseases. PLoS One. 2016;11:e0150733.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Ido A, Moriuchi A, Numata M, et al. Safety and pharmacokinetics of recombinant human hepatocyte growth factor (rh-HGF) in patients with fulminant hepatitis: a phase I/II clinical trial, following preclinical studies to ensure safety. J Transl Med. 2011;9:55.CrossRefPubMedPubMedCentral Ido A, Moriuchi A, Numata M, et al. Safety and pharmacokinetics of recombinant human hepatocyte growth factor (rh-HGF) in patients with fulminant hepatitis: a phase I/II clinical trial, following preclinical studies to ensure safety. J Transl Med. 2011;9:55.CrossRefPubMedPubMedCentral
12.
13.
Zurück zum Zitat Mochida S, Nakayama N, Ido A, et al. Revised criteria for classification of the etiologies of acute liver failure and late-onset hepatic failure in Japan: a report by the Intractable Hepato-biliary Diseases Study Group of Japan in 2015. Hepatol Res. 2016;46:369–71.CrossRefPubMed Mochida S, Nakayama N, Ido A, et al. Revised criteria for classification of the etiologies of acute liver failure and late-onset hepatic failure in Japan: a report by the Intractable Hepato-biliary Diseases Study Group of Japan in 2015. Hepatol Res. 2016;46:369–71.CrossRefPubMed
14.
Zurück zum Zitat Wiegand J, Wedemeyer H, Franke A, et al. Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: a prospective randomized double-blinded multicentre trial. J Viral Hepat. 2014;21:744–50.CrossRefPubMed Wiegand J, Wedemeyer H, Franke A, et al. Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: a prospective randomized double-blinded multicentre trial. J Viral Hepat. 2014;21:744–50.CrossRefPubMed
15.
Zurück zum Zitat Tillmann HL, Hadem J, Leifeld L, et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat. 2006;13:256–63.CrossRefPubMed Tillmann HL, Hadem J, Leifeld L, et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat. 2006;13:256–63.CrossRefPubMed
16.
Zurück zum Zitat Yu JW, Sun LJ, Zhao YH, et al. The study of efficacy of lamivudine in patients with severe acute hepatitis B. Dig Dis Sci. 2010;55:775–83.CrossRefPubMed Yu JW, Sun LJ, Zhao YH, et al. The study of efficacy of lamivudine in patients with severe acute hepatitis B. Dig Dis Sci. 2010;55:775–83.CrossRefPubMed
17.
Zurück zum Zitat Drafting Committee for Hepatitis Management Guidelines and the Japan Society of Hepatology. JSH Guidelines for the management of hepatitis B virus infection. Hepatol Res. 2014;44 Suppl S1:1–58 Drafting Committee for Hepatitis Management Guidelines and the Japan Society of Hepatology. JSH Guidelines for the management of hepatitis B virus infection. Hepatol Res. 2014;44 Suppl S1:1–58
18.
Zurück zum Zitat Yamamoto K, Miyake Y, Ohira H, et al. Prognosis of autoimmune hepatitis showing acute presentation. Hepatol Res. 2013;43:630–8.CrossRefPubMed Yamamoto K, Miyake Y, Ohira H, et al. Prognosis of autoimmune hepatitis showing acute presentation. Hepatol Res. 2013;43:630–8.CrossRefPubMed
19.
Zurück zum Zitat Karkhanis J, Verna EC, Chang MS, et al. Steroid use in acute liver failure. Hepatology. 2014;59:612–21.CrossRefPubMed Karkhanis J, Verna EC, Chang MS, et al. Steroid use in acute liver failure. Hepatology. 2014;59:612–21.CrossRefPubMed
20.
Zurück zum Zitat Kakisaka K, Kataoka K, Suzuki Y, et al. Appropriate timing to start and optimal response evaluation of high-dose corticosteroid therapy for patients with acute liver failure. J Gastroenterol. 2017;52:977–85CrossRefPubMed Kakisaka K, Kataoka K, Suzuki Y, et al. Appropriate timing to start and optimal response evaluation of high-dose corticosteroid therapy for patients with acute liver failure. J Gastroenterol. 2017;52:977–85CrossRefPubMed
21.
Zurück zum Zitat Nalpas B, Francoz C, Ichai P, et al. Prothrombin index slope is an early prognostic marker in patients with severe acute liver diseases. Gut. 2012;61:1098–100.CrossRefPubMed Nalpas B, Francoz C, Ichai P, et al. Prothrombin index slope is an early prognostic marker in patients with severe acute liver diseases. Gut. 2012;61:1098–100.CrossRefPubMed
22.
Zurück zum Zitat Gohda E, Tsubouchi H, Nakayama H, et al. Purification and partial characterization of hepatocyte growth factor from plasma of a patient with fulminant hepatic failure. J Clin Invest. 1988;81:414–9.CrossRefPubMedPubMedCentral Gohda E, Tsubouchi H, Nakayama H, et al. Purification and partial characterization of hepatocyte growth factor from plasma of a patient with fulminant hepatic failure. J Clin Invest. 1988;81:414–9.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Tsubouchi H, Hirono S, Gohda E, et al. Clinical significance of human hepatocyte growth factor in blood from patients with fulminant hepatic failure. Hepatology. 1989;9:875–81.CrossRefPubMed Tsubouchi H, Hirono S, Gohda E, et al. Clinical significance of human hepatocyte growth factor in blood from patients with fulminant hepatic failure. Hepatology. 1989;9:875–81.CrossRefPubMed
24.
Zurück zum Zitat Miyazawa K, Tsubouchi H, Naka D, et al. Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor. Biochem Biophys Res Commun. 1989;163:967–73.CrossRefPubMed Miyazawa K, Tsubouchi H, Naka D, et al. Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor. Biochem Biophys Res Commun. 1989;163:967–73.CrossRefPubMed
25.
Zurück zum Zitat Tsubouchi H, Niitani Y, Hirono S, et al. Levels of the human hepatocyte growth factor in serum of patients with various liver diseases determined by an enzyme-linked immunosorbent assay. Hepatology. 1991;13:1–5.CrossRefPubMed Tsubouchi H, Niitani Y, Hirono S, et al. Levels of the human hepatocyte growth factor in serum of patients with various liver diseases determined by an enzyme-linked immunosorbent assay. Hepatology. 1991;13:1–5.CrossRefPubMed
26.
Zurück zum Zitat Ishiki Y, Ohnishi H, Muto Y, et al. Direct evidence that hepatocyte growth factor is a hepatotrophic factor for liver regeneration and has a potent antihepatitis effect in vivo. Hepatology. 1992;16:1227–35.PubMed Ishiki Y, Ohnishi H, Muto Y, et al. Direct evidence that hepatocyte growth factor is a hepatotrophic factor for liver regeneration and has a potent antihepatitis effect in vivo. Hepatology. 1992;16:1227–35.PubMed
27.
Zurück zum Zitat Kosai K, Matsumoto K, Nagata S, et al. Abrogation of Fas-induced fulminant hepatic failure in mice by hepatocyte growth factor. Biochem Biophys Res Commun. 1998;244:683–90.CrossRefPubMed Kosai K, Matsumoto K, Nagata S, et al. Abrogation of Fas-induced fulminant hepatic failure in mice by hepatocyte growth factor. Biochem Biophys Res Commun. 1998;244:683–90.CrossRefPubMed
28.
Zurück zum Zitat Yasuda H, Imai E, Shiota A, et al. Antifibrogenic effect of a deletion variant of hepatocyte growth factor on liver fibrosis in rats. Hepatology. 1996;24:636–42.CrossRefPubMed Yasuda H, Imai E, Shiota A, et al. Antifibrogenic effect of a deletion variant of hepatocyte growth factor on liver fibrosis in rats. Hepatology. 1996;24:636–42.CrossRefPubMed
29.
Zurück zum Zitat Bussolino F, Di Renzo MF, Ziche M, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol. 1992;119:629–41.CrossRefPubMed Bussolino F, Di Renzo MF, Ziche M, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol. 1992;119:629–41.CrossRefPubMed
30.
Zurück zum Zitat Takikawa Y, Harada M, Wang T, et al. Usefulness and accuracy of the international normalized ratio and activity percent of prothrombin time in patients with liver disease. Hepatol Res. 2014;44:92–101.CrossRefPubMed Takikawa Y, Harada M, Wang T, et al. Usefulness and accuracy of the international normalized ratio and activity percent of prothrombin time in patients with liver disease. Hepatol Res. 2014;44:92–101.CrossRefPubMed
Metadaten
Titel
The recovery of the PT-INR to less than 1.3 predicts survival in patients with severe acute liver injury
verfasst von
Seiichi Mawatari
Akihiro Moriuchi
Fuminori Ohba
Tetsu Kawano
Kohei Oda
Yasuhiro Takikawa
Hajime Takikawa
Akio Ido
Hirohito Tsubouchi
Publikationsdatum
19.12.2017
Verlag
Springer Japan
Erschienen in
Journal of Gastroenterology / Ausgabe 7/2018
Print ISSN: 0944-1174
Elektronische ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-017-1421-3

Weitere Artikel der Ausgabe 7/2018

Journal of Gastroenterology 7/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.